Bartels M, Albert K
Department of Psychiatry, University of Tübingen, Federal Republic of Germany.
J Neural Transm Gen Sect. 1995;99(1-3):1-6. doi: 10.1007/BF01271467.
In vivo 19F resonance spectroscopy measurements of trifluorinated neuroleptics (fluphenazine and trifluoperazine) and later trifluorinated antidepressants (fluoxetine and fluvoxamine) began with animal experiments in 1983. Using rats which have been treated with high oral doses of fluphenazine over a period of three weeks in the beginning of these experiments the measurement time was very long (up to 10 h). The application of better techniques using surface coils led to marked improvement of the signal noise ratio and measurement times in animal experiments could be reduced to minutes. These results encouraged us and other groups to perform experiments in humans to detect and try to estimate brain levels of trifluorinated neuroleptics and antidepressants. The present data of several research groups demonstrate that 19F MR spectroscopy has the potential of becoming a valuable tool for monitoring drug levels at the site of action. The extension of the animal studies to humans might facilitate a better treatment of schizophrenic and depressive patients.
1983年,三氟取代的抗精神病药物(氟奋乃静和三氟拉嗪)以及后来的三氟取代的抗抑郁药物(氟西汀和氟伏沙明)的体内19F磁共振波谱测量始于动物实验。在这些实验开始时,使用高口服剂量氟奋乃静治疗三周的大鼠,测量时间非常长(长达10小时)。使用表面线圈的更好技术的应用显著提高了信噪比,动物实验中的测量时间可缩短至几分钟。这些结果鼓励我们和其他团队在人体中进行实验,以检测并试图估算三氟取代的抗精神病药物和抗抑郁药物在大脑中的水平。几个研究团队目前的数据表明,19F磁共振波谱有潜力成为监测作用部位药物水平的有价值工具。将动物研究扩展到人体可能有助于更好地治疗精神分裂症和抑郁症患者。